Total Payments
$39,474
2024 Payments
$6,959
Companies
18
Transactions
88
Medicare Patients
22
Medicare Billing
$1,947
Payment Breakdown by Category
Consulting$17,790 (45.1%)
Research$15,649 (39.6%)
Travel$4,105 (10.4%)
Food & Beverage$1,930 (4.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,790 | 27 | 45.1% |
| Unspecified | $15,649 | 15 | 39.6% |
| Travel and Lodging | $4,105 | 10 | 10.4% |
| Food and Beverage | $1,930 | 36 | 4.9% |
Payments by Type
General
$23,825
73 transactions
Research
$15,649
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $8,500 | 24 | $0 (2023) |
| Galderma Research & Development, LLC | $6,750 | 5 | $0 (2023) |
| GlaxoSmithKline, LLC. | $6,638 | 12 | $0 (2020) |
| Galderma Laboratories, L.P. | $4,761 | 2 | $0 (2024) |
| Genentech, Inc. | $4,519 | 5 | $0 (2023) |
| Kiniksa Pharmaceuticals, Ltd. | $2,700 | 2 | $0 (2022) |
| AstraZeneca UK Limited | $2,104 | 9 | $0 (2024) |
| Vyaire Medical, Inc. | $2,100 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $945.53 | 9 | $0 (2019) |
| Medical Graphics Corporation | $143.60 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,959 | 15 | Galderma Laboratories, L.P. ($4,761) |
| 2023 | $19,808 | 35 | Regeneron Pharmaceuticals, Inc. ($8,500) |
| 2022 | $2,700 | 2 | Kiniksa Pharmaceuticals, Ltd. ($2,700) |
| 2021 | $2,164 | 2 | Vyaire Medical, Inc. ($2,100) |
| 2020 | $5,230 | 7 | GlaxoSmithKline, LLC. ($5,201) |
| 2019 | $160.29 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($125.00) |
| 2018 | $908.95 | 12 | Boehringer Ingelheim Pharmaceuticals, Inc. ($787.48) |
| 2017 | $1,543 | 12 | GlaxoSmithKline, LLC. ($1,437) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $22.34 | General |
| 11/06/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/04/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/01/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $1,636.25 | Research |
| Study: A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | ||||||
| 05/02/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $3,125.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 02/05/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $478.50 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $461.48 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $407.80 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $230.63 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $159.23 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $150.46 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $149.89 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $38.96 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Respiratory | ||||||
| 11/16/2023 | Galderma Research & Development, LLC | — | — | Cash or cash equivalent | $1,750.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 11/12/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| 11/12/2023 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,470.96 | General |
| 11/12/2023 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $243.21 | General |
| 11/12/2023 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $112.93 | General |
| 11/12/2023 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $51.99 | General |
| 09/14/2023 | Galderma Research & Development, LLC | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab | ||||||
| 04/06/2023 | Galderma Research & Development, LLC | — | — | Cash or cash equivalent | $1,750.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 04/06/2023 | Galderma Research & Development, LLC | — | — | Cash or cash equivalent | $625.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 03/17/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $38.89 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | Galderma Research & Development, LLC | $4,125 | 3 |
| A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | Galderma Laboratories, L.P. | $3,125 | 1 |
| A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation | Kiniksa Pharmaceuticals, Ltd. | $2,700 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab | Galderma Research & Development, LLC | $2,625 | 2 |
| A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | Galderma Laboratories, L.P. | $1,636 | 1 |
| A randomized, double blind, Sponsor open, placebo controlled, 52 week study evaluating the effect of danirixin GSK1325756 on lung function and health related quality of life in participants with mild to moderate Chronic Obstructive Pulmonary Disease CO | GlaxoSmithKline, LLC. | $1,437 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 22 | 23 | $5,035 | $1,947 |
Total Patients
22
Total Services
23
Medicare Billing
$1,947
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 94621 | Test for exercise-induced heart and lung stress | Office | 2021 | 11 | 11 | $4,015 | $1,613 | 40.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 11 | 12 | $1,020 | $333.60 | 32.7% |
About Dr. William Stringer, M.D
Dr. William Stringer, M.D is a Pulmonary Disease healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487633111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Stringer, M.D has received a total of $39,474 in payments from pharmaceutical and medical device companies, with $6,959 received in 2024. These payments were reported across 88 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($17,790).
As a Medicare-enrolled provider, Stringer has provided services to 22 Medicare beneficiaries, totaling 23 services with total Medicare billing of $1,947. Data is available for 1 year (2021–2021), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Torrance, CA
- Active Since 01/11/2006
- Last Updated 01/06/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487633111
Products in Payments
- DUPIXENT (Biological) $8,500
- TRELEGY ELLIPTA (Drug) $5,148
- BREZTRI (Drug) $2,104
- GILOTRIF (Drug) $787.48
- OFEV (Drug) $125.00
- TEFLARO (Drug) $68.72
- TEZSPIRE (Biological) $38.89
- ZERBAXA (Drug) $34.90
- ARCTIC SUN (Device) $29.55
- XARELTO (Drug) $28.43
- DIFICID (Drug) $19.87
- Vabomere (Drug) $18.98
- AVYCAZ (Drug) $17.17
- Yupelri (Drug) $16.31
- VIBATIV (Drug) $16.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Torrance
Richard Casaburi, M.d, M.D
Pulmonary Disease — Payments: $441,702
Pulmonary Disease $441,702
Janine Vintch, M.d, M.D
Pulmonary Disease — Payments: $17,882
Pulmonary Disease $17,882
Divya Thai, Md, MD
Pulmonary Disease — Payments: $12,393
Pulmonary Disease $12,393
Richard Huynh, M.d, M.D
Pulmonary Disease — Payments: $4,294
Pulmonary Disease $4,294
Dr. Mladen Rasic, M.d, M.D
Pulmonary Disease — Payments: $2,724
Pulmonary Disease $2,724
Vanessa Correa, M.d, M.D
Pulmonary Disease — Payments: $1,568
Pulmonary Disease $1,568